Clinicopathological correlations in behavioural variant frontotemporal dementia
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Accurately predicting the underlying neuropathological diagnosis in patients with behavioural variant frontotemporal dementia (bvFTD) poses a daunting challenge for clinicians but will be critical for the success of disease-modifying therapies. We sought to improve pathological prediction by exploring clinicopathological correlations in a large bvFTD cohort. Among 438 patients in whom bvFTD was either the top or an alternative possible clinical diagnosis, 117 had available autopsy data, including 98 with a primary pathological diagnosis of frontotemporal lobar degeneration (FTLD), 15 with Alzheimer's disease, and four with amyotrophic lateral sclerosis who lacked neurodegenerative disease-related pathology outside of the motor system. Patients with FTLD were distributed between FTLD-tau (34 patients: 10 corticobasal degeneration, nine progressive supranuclear palsy, eight Pick's disease, three frontotemporal dementia with parkinsonism associated with chromosome 17, three unclassifiable tauopathy, and one argyrophilic grain disease); FTLD-TDP (55 patients: nine type A including one with motor neuron disease, 27 type B including 21 with motor neuron disease, eight type C with right temporal lobe presentations, and 11 unclassifiable including eight with motor neuron disease), FTLD-FUS (eight patients), and one patient with FTLD-ubiquitin proteasome system positive inclusions (FTLD-UPS) that stained negatively for tau, TDP-43, and FUS. Alzheimer's disease was uncommon (6%) among patients whose only top diagnosis during follow-up was bvFTD. Seventy-nine per cent of FTLD-tau, 86% of FTLD-TDP, and 88% of FTLD-FUS met at least 'possible' bvFTD diagnostic criteria at first presentation. The frequency of the six core bvFTD diagnostic features was similar in FTLD-tau and FTLD-TDP, suggesting that these features alone cannot be used to separate patients by major molecular class. Voxel-based morphometry revealed that nearly all pathological subgroups and even individual patients share atrophy in anterior cingulate, frontoinsula, striatum, and amygdala, indicating that degeneration of these regions is intimately linked to the behavioural syndrome produced by these diverse aetiologies. In addition to these unifying features, symptom profiles also differed among pathological subtypes, suggesting distinct anatomical vulnerabilities and informing a clinician's prediction of pathological diagnosis. Data-driven classification into one of the 10 most common pathological diagnoses was most accurate (up to 60.2%) when using a combination of known predictive factors (genetic mutations, motor features, or striking atrophy patterns) and the results of a discriminant function analysis that incorporated clinical, neuroimaging, and neuropsychological data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because isolated rATL atrophy is highly predictive of TDP-C pathology, recent studies have highlighted the importance of characterizing and isolating this syndrome from other FTD syndromes.6”
From Automated Speech Analysis to Differentiate Frontal and Right Anterior Temporal Lobe Atrophy in Frontotemporal Dementia (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Alternatively, lesions of the Alzheimer type are frequently observed as copathology in post-mortem examination of people who had other neurodegenerative diseases.40,41,94,96”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [96]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, loss of function of GRN alkalinizes lysosomes, while PD-associated mutations in TMEM175, a lysosomal proton leak channels, hyper-acidifies lysosomes.129,130”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [129]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, loss of function of GRN alkalinizes lysosomes, while PD-associated mutations in TMEM175, a lysosomal proton leak channels, hyper-acidifies lysosomes.129,130”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“This biomarker positivity is particularly ambiguous in the case of behavioural or dysexecutive variants, corticobasal syndrome, and semantic or non-fluent variants of primary progressive aphasia, in which the presence of positive Alzheimer’s disease biomarkers can be considered either as Alzheimer’s disease copathology or atypical forms of Alzheimer’s disease94,96,98,99 (appendix p 2).”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [96]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,039
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · cited 3×
“This determination was made by the reviewing clinician as has been done in prior papers establishing the sensitivity and interrater reliability of these criteria (Rascovsky et al., 2011; Lamarre et al., 2013).”
BackgroundMethodSelf-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationFrontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Self-citationHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“Patients were classified into FTLD major molecular classes (tau, TDP-43, or FUS) and subtypes (Mackenzie et al., 2010, 2011), Alzheimer’s disease (Hyman and Trojanowski, 1997; Hyman et al., 2012), or amyotrophic lateral sclerosis (ALS).”
BackgroundSelf-citationAppelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Neurodegenerative Diseases Target Large-Scale Human Brain Networks
Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L., & Greicius, M. D. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.024 · Cited by 2,350
Self-citation
Cited by
Diagnosis and Management of Dementia: Review
Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019) · JAMA · doi:10.1001/jama.2019.4782 · Cited by 1,403
Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051
“Other phenotypes, including the behavioural/dysexecutive variant 70,71 , the cortico-basal variant 72,73 , and the other variants of primary progressive aphasia 69,74 (Supplementary Figure 1), are less commonly related to AD pathology (uncommon AD phenotypes).”
BackgroundSelf-citationThe Salience Network: A Neural System for Perceiving and Responding to Homeostatic Demands
Seeley, W. W. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1138-17.2019 · Cited by 845
“1C) (Perry et al., 2017).”
Self-citationGale, S. A., Acar, D., & Daffner, K. R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.01.022 · Cited by 680
New insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
Self-citationA Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
La Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317
Self-citationComorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease
Spina, S., La Joie, R., Petersen, C., Nolan, A. L., Cuevas, D., Cosme, C., Hepker, M., Hwang, J.-H., Miller, Z. A., Huang, E. J., et al. (2021) · Brain · doi:10.1093/brain/awab099 · Cited by 278
“Genetic analyses were carried out in 137/153 patients as previously described.(43) Genetic screening for pathogenic mutations in the APP, PSEN1, PSEN2, C9orf72, GRN, MAPT, FUS, and TARDBP genes were carried out in 133 patients.”
MethodSelf-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 205
Self-citation18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O’Neil, J. P., Janabi, M., Baker, S., Lee, S. E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0470-7 · Cited by 164
Self-citationRedefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes
Murley, A. G., Coyle-Gilchrist, I., Rouse, M. A., Jones, P. S., Li, W., Wiggins, J., Lansdall, C., Rodríguez, P. V., Wilcox, A., Tsvetanov, K. A., et al. (2020) · Brain · doi:10.1093/brain/awaa097 · Cited by 162
“For example, bvFTD can be associated with tau, TDP-43, FUS protein inclusions or mixed neuropathology (Perry et al. , 2017).”
InfluentialA clinical-radiological framework of the right temporal variant of frontotemporal dementia
Ulugut Erkoyun, H., Groot, C., Heilbron, R., Nelissen, A., van Rossum, J., Jutten, R., Koene, T., van der Flier, W. M., Wattjes, M. P., Scheltens, P., et al. (2020) · Brain · doi:10.1093/brain/awaa225 · Cited by 161
“This finding supports the argument that empathy is associated with the right frontotemporal areas (Rankin et al., 2006; Kamminga et al., 2015; Perry et al., 2017).”
ResultSelf-citationYounes, K., Borghesani, V., Montembeault, M., Spina, S., Mandelli, M. L., Welch, A. E., Weis, E., Callahan, P., Elahi, F. M., Hua, A. Y., et al. (2022) · Brain · doi:10.1093/brain/awac217 · Cited by 152
Self-citationPlasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease
Illán-Gala, I., Lleo, A., Karydas, A., Staffaroni, A. M., Zetterberg, H., Sivasankaran, R., Grinberg, L. T., Spina, S., Kramer, J. H., Ramos, E. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011226 · Cited by 150
“Genetic screening was conducted for mutations known to cause autosomal dominant FTLD or AD (MAPT, C9orf72, GRN, TARDBP, FUS, PSEN1, PSEN2, and APP) at the Coppola Lab at the University of California, Los Angeles.30”
BackgroundMethodInfluentialSelf-citationRegional Glymphatic Abnormality in Behavioral Variant Frontotemporal Dementia
Jiang, D., Liu, L., Kong, Y., Chen, Z., Rosa‐Neto, P., Chen, K., Ren, L., Chu, M., Wu, L., & Initiative, F. L. D. N. (2023) · Annals of Neurology · doi:10.1002/ana.26710 · Cited by 150
Frontotemporal Dementia, Where Do We Stand? A Narrative Review
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411732 · Cited by 145
“…FTD neuropathology can be divided into three main groups: TDP-43 (about 50% of cases), tau (about 40%), and FET, including FUS, EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1), and TAF15 (TATA-box-binding protein-associated factor 15), accounting for 10% of cases [127,128].”
BackgroundReview: neuropathology of non-tau frontotemporal lobar degeneration
Neumann, M., & Mackenzie, I. R. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12526 · Cited by 144
New landscape of the diagnosis of Alzheimer’s disease
Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143
Self-citationOssenkoppele, R., Singleton, E. H., Groot, C., Dijkstra, A. A., Eikelboom, W. S., Seeley, W. W., Miller, B., Laforce, R. J., Scheltens, P., Papma, J. M., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4417 · Cited by 122
Self-citationNeurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology
Nana, A. L., Sidhu, M., Gaus, S. E., Hwang, J.-H. L., Li, L., Park, Y., Kim, E.-J., Pasquini, L., Allen, I. E., Rankin, K. P., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1942-8 · Cited by 128
“, frontoinsular, FI) cortices [8, 66, 87], regardless of the underlying pathological cause [54].”
Self-citationArtificial intelligence for diagnostic and prognostic neuroimaging in dementia: a systematic review
Borchert, R. J., Azevedo, T., Badhwar, A., Bernal, J., Betts, M., Bruffaerts, R., Burkhart, M. C., Dewachter, I., Gellersen, H. M., Low, A., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13412 · Cited by 125
“147 152 Structural MRI was the most frequently used imaging modality (11 of 17 studies).”
MethodNetwork localization of clinical, cognitive, and neuropsychiatric symptoms in Alzheimer’s disease
Tetreault, A. M., Phan, T. X., Orlando, D., Lyu, I., Kang, H., Landman, B. A., Darby, R. R., & Initiative, O. B. O. A. D. N. (2020) · Brain · doi:10.1093/brain/awaa058 · Cited by 130
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
A comprehensive resource for induced pluripotent stem cells from patients with primary tauopathies
Karch, C. M., Kao, A. W., Karydas, A., Onanuga, K., Martinez, R., Argouarch, A., Wang, C., Huang, C., Sohn, P. D., Bowles, K. R., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.09.006 · Cited by 119
Self-citationBede, P., Omer, T., Finegan, E., Chipika, R. H., Iyer, P. M., Doherty, M. A., Vajda, A., Pender, N. P., McLaughlin, R. L., Hutchinson, S., et al. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9837-9 · Cited by 123
“(Perry et al. 2017) Advances in TDP-43 PET ligand development, progress in neurofilament studies and continued improvements in CSF and serum biomarker panels may help to subcategorise patients in future studies based on their underlying pathology.”
BackgroundPatient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy
Brown, J. A., Deng, J., Neuhaus, J., Sible, I. J., Sias, A. C., Lee, S. E., Kornak, J., Marx, G. A., Karydas, A. M., Spina, S., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.08.037 · Cited by 117
“Considering the clinical, anatomical, genetic, and pathological diversity of patients with bvFTD (Perry et al., 2017), we suspected that our model may have failed in some patients based on a different underlying biology such as the presence of a C9orf72 expansion or other genetic mutation.”
BackgroundSelf-citationJohnen, A., & Bertoux, M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00594 · Cited by 101
“Currently, no methods allow the detection or prediction of FTLD pathologies during the life of patients and no reliable biomarker exists for the diagnosis of bvFTD, although some associations between genetics and post-mortem histopathological findings have been established (13, 18).”
MethodAlzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Neumann, M., Lee, E. B., & Mackenzie, I. R. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-51140-1_13 · Cited by 103
GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition
Murley, A. G., Rouse, M. A., Jones, P. S., Ye, R., Hezemans, F. H., O’Callaghan, C., Frangou, P., Kourtzi, Z., Rua, C., Carpenter, T. A., et al. (2020) · Brain · doi:10.1093/brain/awaa305 · Cited by 100
“Therefore, we use a transdiagnostic approach when reporting these results and refer to all patients with bvFTD or PSP as an ‘FTLD’ group, noting the high, but not perfect, clinical pathological correlations between clinically probable and possible bvFTD, PSP and the pathologies of FTLD (Perry et al., 2017; Gazzina et…”
MethodMajumder, V., Gregory, J. M., Barria, M. A., Green, A., & Pal, S. (2018) · BMC Neurology · doi:10.1186/s12883-018-1091-7 · Cited by 101
Physiological changes in neurodegeneration—mechanistic insights and clinical utility
Ahmed, R. M., Ke, Y. D., Vucic, S., Ittner, L. M., Seeley, W., Hodges, J. R., Piguet, O., Halliday, G., & Kiernan, M. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.23 · Cited by 91
Self-citationVillain, N., Planche, V., Lilamand, M., Cordonnier, C., Soto‐Martin, M., Mollion, H., Bombois, S., & Delrieu, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100094 · Cited by 95
Molecular imaging in dementia: Past, present, and future
Laforce, R., Soucy, J., Sellami, L., Dallaire‐Théroux, C., Brunet, F., Bergeron, D., Miller, B. L., & Ossenkoppele, R. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.2855 · Cited by 88
“[122] Perry DC, Brown JA, Possin KL, Datta S, Trujillo A, Radke A, et al.”
BackgroundSelf-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 90
“AD pathology is a relatively rare cause of the behavioral variant of FTD ( 173,178 ) and non fl uent/agrammatic or semantic variants of PPA ( 174,175 ).”
Self-citationC9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies
Vatsavayai, S. C., Nana, A. L., Yokoyama, J. S., & Seeley, W. W. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1921-0 · Cited by 83
Self-citationYounes, K., & Miller, B. L. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.006 · Cited by 72
Self-citationSpeech and language impairments in behavioral variant frontotemporal dementia: A systematic review
Geraudie, A., Battista, P., García, A. M., Allen, I. E., Miller, Z. A., Gorno-Tempini, M. L., & Montembeault, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.015 · Cited by 80
Self-citationBorghesani, V., Narvid, J. A., Battistella, G., Shwe, W., Watson, C., Binney, R. J., Sturm, V. E., Miller, Z., Mandelli, M. L., Miller, B. L., et al. (2019) · Cortex · doi:10.1016/j.cortex.2019.01.006 · Cited by 86
“, 2017), while bvFTD cases present more variability across FTLD subtypes (Perry et al., 2017).”
BackgroundSelf-citationPrimary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD
Robinson, J. L., Yan, N., Caswell, C., Xie, S. X., Suh, E., Van Deerlin, V. M., Gibbons, G., Irwin, D. J., Grossman, M., Lee, E. B., et al. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz141 · Cited by 75
Self-citationSpeech and language impairments in behavioral variant frontotemporal dementia: A systematic review
(2021) · doi:10.1101/2021.07.10.21260313 · Cited by 78
“, 2017) or word comprehension, but repetition scores were lower in AD than in FTLD patients (Perry et al., 2017).”
BackgroundInfluentialBejanin, A., Murray, M. E., Martin, P. R., Botha, H., Tosakulwong, N., Schwarz, C. G., Senjem, M. L., Chételat, G., Kantarci, K., Jack, C. R., et al. (2019) · Brain · doi:10.1093/brain/awz277 · Cited by 77
“65 and used to compute a frequency map of grey matter atrophy (Ossenkoppele et al., 2015; Perry et al., 2017).”
MethodPeet, B. T., Spina, S., Mundada, N., & La Joie, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01101-x · Cited by 74
Cellular and regional vulnerability in frontotemporal tauopathies
Forrest, S. L., Kril, J. J., & Halliday, G. M. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02035-7 · Cited by 85
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Self-citationVandeVrede, L. A., Cho, H., Sanderson‐Cimino, M. E., Wekselman, F., Cobigo, Y., Gorno‐Tempini, M. L., Heuer, H. W., Kramer, J. H., Lago, A. L., Leichter, D., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2024.5017 · Cited by 69
Self-citationThe functional neuroanatomy of emotion processing in frontotemporal dementias
Marshall, C. R., Hardy, C. J. D., Russell, L. L., Bond, R. L., Sivasathiaseelan, H., Greaves, C., Moore, K. M., Agustus, J. L., van Leeuwen, J. E. P., Wastling, S. J., et al. (2019) · Brain · doi:10.1093/brain/awz204 · Cited by 64
“Larger patient cohorts with histopathological and genetic correlation will be required to define the pathophysiological phenotypes delineated here fully (Perry et al. , 2017).”
Illán‐Gala, I., Casaletto, K. B., Borrego‐Écija, S., Arenaza‐Urquijo, E. M., Wolf, A., Cobigo, Y., Goh, S. Y. M., Staffaroni, A. M., Alcolea, D., Fortea, J., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12299 · Cited by 66
“Quality ofMRI,** 80 (7) 86 (1) 82 (6) 84 (3) 84 (2) 84 (3)”
BackgroundSelf-citationMalarte, M.-L., Gillberg, P.-G., Kumar, A., Bogdanovic, N., Lemoine, L., & Nordberg, A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01875-2 · Cited by 67
“The main impact of this complexity can be seen in clinical settings where confounding factors between tauopathies often lead to a misdiagnosis [37, 38].”
BackgroundClinical Spectrum of Tauopathies
Olfati, N., Shoeibi, A., & Litvan, I. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.944806 · Cited by 71
“Results showed no difference between brainstem and cortical variants, but of note, possible PSP-SL patients had less midbrain atrophy while PSP-CBS and PSP-F patients had highly abnormal indices.”
BackgroundResultInfluentialGelon, P. A., Dutchak, P. A., & Sephton, C. F. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1000183 · Cited by 70
“These cases usually present as bvFTD or FTD-MND and tend to effect younger individuals having more rapid disease progress (Perry et al., 2017).”
BackgroundThe path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases
Baldacci, F., Mazzucchi, S., Vecchia, A. D., Giampietri, L., Giannini, N., Koronyo‐Hamaoui, M., Ceravolo, R., Siciliano, G., Bonuccelli, U., Elahi, F. M., et al. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1731306 · Cited by 68
“Progranulin and poly(GP) are the most studied, potentially useful in the differential diagnosis between tau and TDP-43 subtypes [183].”
BackgroundBehavioral Variant Frontotemporal Dementia
Seeley, W. W. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000698 · Cited by 75
Self-citationIllán-Gala, I., Montal, V., Borrego-Écija, S., Vilaplana, E., Pegueroles, J., Alcolea, D., Sánchez-Saudinós, B., Clarimón, J., Turón-Sans, J., Bargalló, N., et al. (2019) · Brain · doi:10.1093/brain/awz031 · Cited by 60
Self-citationRegional and hemispheric susceptibility of the temporal lobe to FTLD-TDP type C pathology
Borghesani, V., Battistella, G., Mandelli, M. L., Welch, A., Weis, E., Younes, K., Neuhaus, J., Grinberg, L. T., Seeley, W. M., Spina, S., et al. (2020) · NeuroImage: Clinical · doi:10.1016/j.nicl.2020.102369 · Cited by 60
“It should be stressed that while svPPA/temporal variant FTD are overwhelmingly associated with TDP43-C, bvFTD presents considerably more pathological variability (Perry et al., 2017).”
Self-citationGhirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59
“Coexistence of high likelihood of ADNC is rare.(14,16,17) We found the highest frequency of plaques in PSP, although this was likely to be related to the older age of the PSP cohort.”
BackgroundClinico-genetic findings in 509 frontotemporal dementia patients
Wagner, M., Lorenz, G., Volk, A. E., Brunet, T., Edbauer, D., Berutti, R., Zhao, C., Anderl‐Straub, S., Bertram, L., Danek, A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01271-2 · Cited by 61
Resveratrol and Alzheimer's disease. From molecular pathophysiology to clinical trials
Drygalski, K., Fereniec, E., Koryciński, K., Chomentowski, A., Kiełczewska, A., Odrzygóźdź, C., & Modzelewska, B. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.09.019 · Cited by 63
Biomarkers for diseases with TDP-43 pathology
Steinacker, P., Barschke, P., & Otto, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.10.003 · Cited by 57
Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers
Lee, S. E., Sias, A. C., Kosik, E. L., Flagan, T. M., Deng, J., Chu, S. A., Brown, J. A., Vidovszky, A. A., Ramos, E. M., Gorno-Tempini, M. L., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101751 · Cited by 53
Self-citationCSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
Constantinides, V. C., Paraskevas, G. P., Boufidou, F., Bourbouli, M., Pyrgelis, E.-S., Stefanis, L., & Kapaki, E. N. (2023) · Diagnostics · doi:10.3390/diagnostics13040783 · Cited by 54
Overview of therapeutic targets in management of dementia
Malik, R., Kalra, S., Bhatia, S., Al‐Harrasi, A., Singh, G., Mohan, S., Makeen, H. A., Albratty, M., Meraya, A. M., Bahar, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113168 · Cited by 55
Neurodegenerative disease of the brain: a survey of interdisciplinary approaches
Davenport, F., Gallacher, J., Kourtzi, Z., Koychev, I. G., Matthews, P. M., Oxtoby, N. P., Parkes, L. M., Priesemann, V., Rowe, J. B., Smye, S. W., et al. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0406 · Cited by 55
“For example, tau versus TDP-43-associated behavioural variant frontotemporal dementia can be clinically indistinguishable [22].”
BackgroundBenussi, A., Alberici, A., Ferrari, C., Cantoni, V., Dell’Era, V., Turrone, R., Cotelli, M. S., Binetti, G., Paghera, B., Koch, G., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0423-6 · Cited by 50
RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration
Hofmann, J. W., Seeley, W. W., & Huang, E. J. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012955 · Cited by 47
“Most patients with FTLD-FUS present with behavioral variant FTD or FTD–motor neuron disease and tend to be younger and have a more rapidly progressive clinical course, with extreme anterior striatal atrophy as well as atrophy in typical FTD-related cortical areas (43).”
BackgroundSelf-citationCerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
Ljubenkov, P. A., Staffaroni, A. M., Rojas, J. C., Allen, I. E., Wang, P., Heuer, H., Karydas, A., Kornak, J., Cobigo, Y., Seeley, W. W., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.643 · Cited by 49
Self-citationLuan, Y., Wang, W., Huang, Q., Wang, Y., Nussbaumer, J., Wang, J., Steward, A., Roemer, S. N., Guan, Y., Ewers, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61497-4 · Cited by 51
“To quantify the change of synaptic density in A β + participants, we adopted to a prior approach 38,39 .”
Lin, L.-C., Nana, A. L., Hepker, M., Hwang, J.-H. L., Gaus, S. E., Spina, S., Cosme, C. G., Gan, L., Grinberg, L. T., Geschwind, D. H., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0809-0 · Cited by 52
Self-citationFrontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology
Scarioni, M., Gami‐Patel, P., Timar, Y. S. S., Seelaar, H., Swieten, J. C. V., Rozemüller, A. J. M., Dols, A., Scarpini, E. A., Galimberti, D., Bank, N. B., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25739 · Cited by 51
“The higher prevalence of hyperorality in pathologically confirmed FTLD donors compared to Alzheimer’s disease donors has been described before when focusing on the clinical diagnosis of bvFTD.(18) Our work supports the finding from a recent clinical cohort study that hyperorality is detectable not only in bvFTD but al…”
BackgroundResultInfluentialMcCarthy, J., Collins, D. L., & Ducharme, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.08.028 · Cited by 47
“Larger multi-site datasets will also be important to develop deep learning approaches for categorical diagnostic classification, disease course prediction and to build models that could predict pathological subtypes in vivo (Perry et al., 2017).”
Illán‐Gala, I., Nigro, S. L., VandeVrede, L. A., Falgàs, N., Heuer, H. W., Painous, C., Compta, Y., Martí, M. J., Montal, V., Pagonabarraga, J., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.9588 · Cited by 49
Self-citationSamudra, N. P., Fischer, D. L., Lenio, S., Lago, A. L., Ljubenkov, P. A., Rojas, J. C., Seeley, W. W., Spina, S., Staffaroni, A. M., Tablante, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13799 · Cited by 48
Self-citationCurrent radiotracers to image neurodegenerative diseases
Tiepolt, S., Patt, M., Aghakhanyan, G., Meyer, P., Hesse, S., Barthel, H., & Sabri, O. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0070-7 · Cited by 51
Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications
Azevedo, R., Jacquemin, C., Villain, N., Fenaille, F., Lamari, F., & Bécher, F. (2022) · Cells · doi:10.3390/cells11081279 · Cited by 46
“There is a substantial overlap in the clinical symptoms of these diseases, which complicates an effective and accurate diagnosis, particularly in the early stages [4,15].”
BackgroundDiagnostic challenges in rapidly progressive dementia
Zerr, I., & Hermann, P. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1519397 · Cited by 46
Changing perspectives on frontotemporal dementia: A review
Snowden, J. S. (2022) · Journal of Neuropsychology · doi:10.1111/jnp.12297 · Cited by 51
Heuer, H. W., Wang, P., Rascovsky, K., Wolf, A., Appleby, B., Bove, J., Bordelon, Y., Brannelly, P., Brushaber, D. E., Caso, C., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12046 · Cited by 43
Self-citationRETRACTED: Osthole attenuates APP-induced Alzheimer's disease through up-regulating miRNA-101a-3p
Lin, Y., Liang, X., Yao, Y., Xiao, H., Shi, Y., & Yang, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.004 · Cited by 47
Retracted18F-MK-6240 tau-PET in genetic frontotemporal dementia
Levy, J. P., Bezgin, G., Savard, M., Pascoal, T. A., Finger, E. C., Laforce, R. J., Sonnen, J. A., Soucy, J., Gauthier, S. G., Rosa‐Neto, P., et al. (2021) · Brain · doi:10.1093/brain/awab392 · Cited by 45
“The only way to definitively determine the pathological subtype of frontotemporal lobar degeneration (FTLD) currently is by autopsy, unless the patient has a genetic form of the disease.(4) Approximately 15– 30% of FTD cases are caused by an autosomal dominant, full penetrance mutation for which the pathology is presu…”
BackgroundDucharme, S., Pearl-Dowler, L., Gossink, F., McCarthy, J., Lai, J., Dickerson, B. C., Chertkow, H., Rapin, L., Vijverberg, E., Krudop, W., et al. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180839 · Cited by 42
“Biomarkers hold a lot of promise to improve diagnostic accuracy in the early stage, including cerebrospinal fluid (CSF) markers such as neurofilament light chains and phosphorylated tau [15], in addition to MRI morphometric processing with machine-learning classifications [16, 17].”
Tisdall, M. D., Ohm, D. T., Lobrovich, R., Das, S. R., Mizsei, G., Prabhakaran, K., Ittyerah, R., Lim, S., McMillan, C. T., Wolk, D. A., et al. (2022) · NeuroImage: Clinical · doi:10.1016/j.nicl.2021.102913 · Cited by 38
“(Irwin et al., 2015; Gorno-Tempini et al., 2011; H ¨ oglinger et al., 2017; Giannini et al., 2019; Irwin et al., 2018; Perry et al., 2017; Spinelli et al., 2017) Moreover, while various degenerative processes can be detected using structural, (McKiernan and O ’ Brien, 2017; McMillan et al., 2014;…”
Self-citationGlial cells and adaptive immunity in frontotemporal dementia with tau pathology
Hartnell, I. J., Blum, D., Nicoll, J. A. R., Dorothee, G., & Boche, D. (2021) · Brain · doi:10.1093/brain/awaa457 · Cited by 42
Ward, J. M., Ly, M. J., & Raji, C. A. (2022) · PET Clinics · doi:10.1016/j.cpet.2022.09.010 · Cited by 45
Police Interactions Among Neuropathologically Confirmed Dementia Patients: Prevalence and Cause
Liljegren, M., Waldö, M. L., Rydbeck, R., & Englund, E. M. (2018) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000267 · Cited by 40
Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies
Spina, S., Brown, J. A., Deng, J., Gardner, R. C., Nana, A. L., Hwang, J.-H. L., Gaus, S. E., Huang, E. J., Kramer, J. H., Rosen, H. J., et al. (2019) · Brain · doi:10.1093/brain/awz122 · Cited by 39
Self-citationAtypical Alzheimer Disease Variants
Polsinelli, A. J., & Apostolova, L. G. (2022) · Continuum · doi:10.1212/con.0000000000001082 · Cited by 39
SV2A PET imaging in human neurodegenerative diseases
Bavarsad, M. S., & Grinberg, L. T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380561 · Cited by 39
Self-citationWhat Do We Mean by Behavioral Disinhibition in Frontotemporal Dementia?
Magrath Guimet, N., Miller, B. L., Allegri, R. F., & Rankin, K. P. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.707799 · Cited by 38
Self-citationIn vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use
López‐Carbonero, J. I., García-Toledo, I., Fernández-Hernández, L., Bascuñana, P., Moreno, M., Matías‐Guiu, J. A., & Corrochano, S. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00419-8 · Cited by 40
Giannini, L., Peterson, C. S., Ohm, D. T., Xie, S. X., McMillan, C. T., Raskovsky, K., Massimo, L. M., Suh, E. R., Deerlin, V. M. V., Wolk, D. A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01129-2 · Cited by 37
Self-citationShiells, H., Schelter, B. O., Bentham, P., Baddeley, T. C., Rubino, C. M., Ganesan, H., Hammel, J., Vuksanović, V., Staff, R. T., Murray, A. D., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191173 · Cited by 35
“This is similar to the frequency previously reported for bvFTD patients having tau mutations (3%) [23].”
BackgroundResultInfluentialFriedberg, A., Pasquini, L., Diggs, R. T., Glaubitz, E. A., López, L., Illán‐Gala, I., Iaccarino, L., Joie, R. L., Mundada, N. S., Knudtson, M. V., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0001 · Cited by 39
Self-citationUniform data set language measures for bvFTD and PPA diagnosis and monitoring
Staffaroni, A. M., Weintraub, S., Rascovsky, K., Rankin, K. P., Taylor, J., Fields, J. A., Casaletto, K. B., Hillis, A. E., Lukic, S., Gorno‐Tempini, M. L., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12148 · Cited by 33
Self-citationBergeron, D., Sellami, L., Poulin, S. P., Verret, L., Bouchard, R. W., & Laforce, R. J. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000511210 · Cited by 31
Calderón‐Garcidueñas, L., Hernández-Luna, J., Mukherjee, P. S., Styner, M. A., Chávez-Franco, D. A., Luévano-Castro, S. C., Crespo-Cortés, C. N., Stommel, E. W., & Torres‐Jardón, R. (2022) · Toxics · doi:10.3390/toxics10040156 · Cited by 33
Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degeneration
Forrest, S. L., Crockford, D. R., Sizemova, A., McCann, H., Shepherd, C. E., McGeachie, A. B., Affleck, A. J., Carew‐Jones, F., Bartley, L., Kwok, J. B., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007530 · Cited by 30
“Approximately 10% of all patients with FTLD develop clinically relevant parkinsonism,(2,25) and a recent study demonstrates that parkinsonism is equally prevalent in FTLD-tau and FTLD-TDP.(34) Similarly, it is not uncommon for patients with PD to develop dementia and features of frontal lobe dysfunction including exec…”
BackgroundLinking Personalized Brain Atrophy to Schizophrenia Network and Treatment Response
Ji, G., Zalesky, A., Wang, Y., He, K., Wang, L., Du, R., Sun, J., Bai, T., Chen, X., Tian, Y., et al. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac162 · Cited by 29
Cortical microstructure in primary progressive aphasia: a multicenter study
Illán‐Gala, I., Montal, V., Borrego‐Écija, S., Mandelli, M. L., Falgàs, N., Welch, A. E., Pegueroles, J., Santos‐Santos, M., Bejanin, A., Alcolea, D. A., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00974-0 · Cited by 29
Self-citationNetwork Localization of Alien Limb in Patients with Corticobasal Syndrome
Tetreault, A. M., Phan, T. X., Petersen, K. J., Claassen, D. O., Neth, B. J., Graff‐Radford, J., Albrecht, F., Fließbach, K., Schneider, A., Synofzik, M., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25901 · Cited by 32
Metadata
- Authors
- Perry, D. C., Brown, J. A., Possin, K. L., Datta, S., Trujillo, A., Radke, A., Karydas, A., Kornak, J., Sias, A. C., Rabinovici, G. D., Gorno-Tempini, M. L., Boxer, A. L., De May, M., Rankin, K. P., Sturm, V. E., Lee, S. E., Matthews, B. R., Kao, A. W., Vossel, K. A., Tartaglia, M. C., Miller, Z. A., Seo, S. W., Sidhu, M., Gaus, S. E., Nana, A. L., Vargas, J. N. S., Hwang, J.-H. L., Ossenkoppele, R., Brown, A. B., Huang, E. J., Coppola, G., Rosen, H. J., Geschwind, D., Trojanowski, J. Q., Grinberg, L. T., Kramer, J. H., Miller, B. L., & Seeley, W. W.
- Affiliations
- University of California, San Francisco (US)
- Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA
- University of Minnesota (US)
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Corresponding author
- Perry, David C
- ORCID
- Perry, David C
- Brown, Jesse A
- Possin, Katherine L
- Kornak, John
- Sias, Ana C
- Rabinovici, Gil D
- Boxer, Adam L
- Rankin, Katherine P
- Sturm, Virginia E
- Lee, Suzee E
- Kao, Aimee W
- Vossel, Keith A
- Tartaglia, Maria Carmela
- Miller, Zachary A
- Seo, Sang Won
- Nana, Alissa L
- Vargas, Jose Norberto S
- Ossenkoppele, Rik
- Huang, Eric J
- Coppola, Giovanni
- Rosen, Howard J
- Geschwind, Daniel
- Trojanowski, John Q
- Grinberg, Lea T
- Kramer, Joel H
- Miller, Bruce L
- Seeley, William W
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-06
- Volume
- 140
- Issue
- 12
- Pages
- 3329-3345
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC5841140
- OpenAlex
- W2760832975
- Cited by
- 309
- References
- 54
- Citations by year
- 2026: 15 · 2025: 39 · 2024: 35 · 2023: 38 · 2022: 56 · 2021: 39 · 2020: 29 · 2019: 34 · 2018: 23 · 2017: 1
- FWCI
- 19.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- PMC
- Funders
- National Institutes of Health (P01AG019724, P50AG023501, P30AG10124, P01AG17856, K23AG045289, U54NS092089, R01AG038791)
- BrightFocus Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- behavioral variant frontotemporal dementia, clinicopathological correlation, frontotemporal lobar degeneration, FTLD-tau, FTLD-TDP, corticobasal degeneration, progressive supranuclear palsy, Pick's disease, motor neuron disease, Alzheimer's disease, voxel-based morphometry, brain atrophy, behavioral syndromes, disease-modifying therapy, symptom profiles, neuropathology
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Autopsy, Brain, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Organ Size, Supranuclear Palsy, Progressive, Pick Disease of the Brain, Frontotemporal Lobar Degeneration, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.